Dallas, Texas (PRWEB) September 29, 2014
The global epilepsy market was valued at an estimated $4.2 billion in 2012. GlobalData expects the market to grow to $5.35 billion by 2022, with more than 50% of sales coming from the US. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction.
Major drivers of market growth over this forecast period will include:
Major barriers to the growth of the epilepsy market will include:
Complete Report Details Available at http://www.marketoptimizer.org/pharmapoint-epilepsy-global-drug-forecast-and-market-analysis-to-2022-event-driven-update.html .
Key Questions Answered
Key Findings
Order a Purchase Copy at http://www.marketoptimizer.org/contacts/purchase?rname=10715 . (This is a premium report priced at US$10995 for a single user License.)
Company Profiles include in report:
Companies Seek to Compete in a Crowded Epilepsy Market Through Novel Drug Developent, Strategic Licensing and Acquisitions, and Expansion into New Markets
Original post:
Global Sales of Epilepsy Drugs Market to Grow $5.35 billion by 2022 Says a New Report Available at MarketOptimizer.org